About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

Cuorips Inc.(4894) Summary

4894
TSE Growth
Cuorips Inc.
7,440
JPY
-160
(-2.11%)
Apr 4, 3:30 pm JST
50.93
USD
Apr 4, 2:30 am EDT
Result
PTS
outside of trading hours
7,200
Apr 4, 8:01 pm JST
Summary Chart Historical News Financial Result
PER
PBR
11.1
Yield
ー%
Margin Trading Ratio
306.76
Stock Price
Apr 4, 2025
Opening Apr 4, 9:00 am
7,560 JPY 51.69 USD
Previous Close Apr 3
7,600 JPY 51.61 USD
High Apr 4, 9:00 am
7,790 JPY 53.31 USD
Low Apr 4, 12:41 pm
7,200 JPY 49.40 USD
Volume
322,500
Trading Value
2.42B JPY 0.02B USD
VWAP
7496.1 JPY 51.33 USD
Minimum Trading Value
744,000 JPY 5,093 USD
Market Cap
0.06T JPY 0.41B USD
Number of Trades
1,703
Liquidity & Number of Trades
As of Apr 4, 2025
Liquidity
High
1-Year Average
1,630
1-Year High May 29, 2024
22,354
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 28, 2025 1,500 841,700 561.13
Mar 21, 2025 1,800 793,500 440.83
Mar 14, 2025 1,400 786,400 561.71
Mar 7, 2025 1,300 760,100 584.69
Feb 28, 2025 1,400 762,100 544.36
Company Profile
Cuorips Inc. specializes in the development and commercialization of iPS cell-derived cardiomyocyte sheets.
Sector
Pharmaceuticals
Cuorips Inc. focuses on the development and commercialization of human iPS cell-derived cardiomyocyte sheets, working towards the practical application of regenerative medicine products. Through collaborative research with Osaka University and partnerships with major pharmaceutical companies, Cuorips has established advanced cell cultivation techniques. The company's products are expected to improve cardiac function and aid recovery from heart failure in patients with severe cardiac conditions. Utilizing its proprietary commercial cell culture and processing facility "CLiC-1", Cuorips also engages in Contract Development and Manufacturing Organization (CDMO) services and cell culture supernatant businesses. The CDMO services include development support and contract manufacturing, providing various cells as raw materials. The cell culture supernatant business effectively utilizes the liquid byproduct from the cell cultivation process. Cuorips aims to realize a wide range of regenerative medicine technologies, including the development of new catheter-based treatments and research on in vivo regeneration factor inducers.